Kusajili – Centralise les essais cliniques mondiaux

[Trial of device that is not approved or cleared by the U.S. FDA]

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

PRESERVE-Zenith® Iliac Branch System Clinical Extended Study The PRESERVE-Zenith® Iliac Branch System Clinical Study is a clinical trial to collect confirmatory safety and effectiveness data on the Zenith® Branch Endovascular Graft-Iliac Bifurcation System. This system is made up of two devices: the Zenith® Branch Endovascular Graft-Iliac Bifurcation and the ConnectSX™ covered stent in the treatment of aorto-iliac and iliac aneurysms

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Expanded Access of Cabozantinib in Medullary Thyroid Cancer The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.

• Pays United States,
• Organes Aucun
• Spécialités Aucun

[Trial of device that is not approved or cleared by the U.S. FDA]

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

[Trial of device that is not approved or cleared by the U.S. FDA]

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, PHASE 1 STUDY TO DEMONSTRATE THE EQUIVALENCE WITH RESPECT TO THE PHARMACOKINETIC PROFILE OF CT-P13 AND REMICADE IN PATIENTS WITH ANKYLOSING SPONDYLITIS

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

[Trial of device that is not approved or cleared by the U.S. FDA]

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea. Randomised, double-blind, placebo-controlled trial

• Pays Germany,
• Organes Aucun
• Spécialités Aucun

A PHASE II/III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE SAFETY AND EFFICACY OF TIOTORPIUM INHALATION SOLUTION (2.5 µG AND 5µG) ADMINISTERED ONCE DAILY IN THE AFTERNOON VIA RESPIMAT® INHALER FOR 12 WEEKS INPATIENTS 1 TO 5 YEARS OLD WITH PERSISTENT ASTHMA

• Pays Aucun
• Organes Aucun
• Spécialités Aucun